PolyPeptide Group Ltd

Latest Results (30.09.2026):

PolyPeptide Group Ltd — Q4 2024 (year ended 31 December 2024): The Group reported full-year 2024 results (consolidated). Revenue increased to 336,792 kEUR (2023: 320,372 kEUR) and the net loss narrowed to -19,564 kEUR (2023: -51,440 kEUR), delivering a materially improved operating result (EBIT -7,364 kEUR vs -36,468 kEUR). Earnings per share were -0.59 EUR (2023: -1.56 EUR). The year included significant capex and an increase in contract liabilities; cash and cash equivalents declined to 68,277 kEUR at year-end.

Revenue

Full-year revenue: 336,792 kEUR in 2024, up from 320,372 kEUR in 2023 (≈ +5.1% year-on-year).

Profitability / Operating result

Gross profit rose to 39,348 kEUR (2023: 9,123 kEUR). Operating expenses were broadly flat at -46,712 kEUR (2023: -45,591 kEUR). EBIT loss narrowed substantially to -7,364 kEUR (2023: -36,468 kEUR).

Net result and EPS

Result for the year was a loss of -19,564 kEUR (2023: -51,440 kEUR). Basic & diluted EPS improved to -0.59 EUR (2023: -1.56 EUR).

Financial result

Net financial result improved to -10,781 kEUR (2023: -21,775 kEUR). Notably, financial income rose to 6,802 kEUR (2023: 103 kEUR), reducing the overall financing drag.

Cash flow, capex and cash position

Net cash from operating activities was strong at 89,399 kEUR (2023: 36,485 kEUR). Investing outflows were large (-91,018 kEUR) driven by property, plant and equipment additions. Cash and cash equivalents fell to 68,277 kEUR at year-end (2023: 95,706 kEUR); net movement in cash was -26,942 kEUR.

Balance sheet and leverage

Total assets: 756,576 kEUR (2023: 689,088 kEUR). Equity decreased to 357,244 kEUR (2023: 381,225 kEUR). Interest‑bearing borrowings totaled 70,062 kEUR (39,420 kEUR non‑current + 30,642 kEUR current), implying a near‑neutral net debt position versus cash of 68,277 kEUR (approximate net borrowings ≈ 1,785 kEUR).

Working capital and deferred revenue

Inventories increased to 146,351 kEUR (2023: 128,507 kEUR). Contract liabilities (deferred revenue) rose materially to 160,114 kEUR total (non‑current 99,639 kEUR; current 60,475 kEUR), reflecting advanced billings or milestone receipts.

Pensions and provisions

Pension liabilities increased to 32,133 kEUR (2023: 25,111 kEUR). Total provisions remain modest (non‑current 1,942 kEUR).

Overall view

PolyPeptide Group Ltd’s 2024 results show clear operational improvement with higher revenues, markedly better gross profit and a much smaller net loss versus 2023, but the year involved significant investment (capex), growth in deferred revenue, and a lower cash balance at year-end. EPS improved accordingly but remained negative for the year.